Blog
RSS FeedPosted by Michael Wonder on 12 Jan 2017
Additional listings on the Pharmaceutical Schedule of a range of orthopaedic joint implants, additional CMF implants, associated products and bone cement with Stryker
12 January 2017 - PHARMAC is pleased to announce the approval of an amendment to the trauma, spine and CMF ...
Posted by Michael Wonder on 21 Dec 2016
Decision to list oral betaine for rare disorder
21 December 2016 - PHARMAC is pleased to announce the approval of an agreement with Emerge Health to list oral ...
Posted by Michael Wonder on 15 Dec 2016
Decision relating to anti-VEGF treatments for ophthalmic use
15 December 2016 - On 5 September 2016, PHARMAC consulted on a proposal to list ranibizumab (Lucentis) and aflibercept (Eylea) ...
Posted by Michael Wonder on 06 Dec 2016
Clostridium botulinum type A toxin (Botox) in DHB hospitals
6 December 2016 - PHARMAC is seeking feedback on a proposal to amend the contractual terms of listing for clostridium botulinum ...
Posted by Michael Wonder on 05 Dec 2016
PHARMAC funds breast cancer drug Perjeta
5 December 2016 - More breast cancer sufferers will soon have access to a treatment programme that can extend lives ...
Posted by Michael Wonder on 14 Nov 2016
Decision to list enzyme replacement therapies for some rare disorders
11 November 2016 - PHARMAC is pleased to announce the approval of an agreement with Sanofi-Aventis for the listing of ...
Posted by Michael Wonder on 31 Oct 2016
Proposal to list and award sole supply to celecoxib Pfizer
31 October 2016 - Following a request for proposals for the supply of selective cyclooxygenase-2 inhibitors of the ‘coxib’ class ...
Posted by Michael Wonder on 17 Oct 2016
Decision to list cholic acid (Cholebiol) for rare disorder
17 October 2016 - PHARMAC is pleased to announce the approval of an agreement with Max Health Limited for the ...
Posted by Michael Wonder on 12 Oct 2016
Decision to award sole supply of venlafaxine
12 October 2016 - PHARMAC is pleased to announce a decision to award a sole supply arrangement for venlafaxine hydrochloride ...
Posted by Michael Wonder on 11 Oct 2016
Multi-product proposal involving nine pharmaceuticals
11 October 2016 - PHARMAC is seeking feedback on a proposal to fund three new treatments, widen access to three ...
Posted by Michael Wonder on 11 Oct 2016
Decision regarding funding of the HIV treatments dolutegravir (Tivicay) and abacavir sulphate with lamivudine (Kivexa)
11 October 2016 - PHARMAC is pleased to announce that the approval of an agreement with GlaxoSmithKline for the funding ...
Posted by Michael Wonder on 06 Oct 2016
Wound care decision points to future direction of devices work
6 October 2016 - PHARMAC is entering a new phase of its national hospital medical device contracting, as it implements ...
Posted by Michael Wonder on 30 Aug 2016
Decision to award sole supply to Zoladex and reference price Eligard and Lucrin
30 August 2016 - PHARMAC has made decisions to award the Zoladex brand of goserelin acetate sole subsidised supply in the ...
Posted by Michael Wonder on 09 Aug 2016
Proposal to award sole supply of leflunomide
9 August 2016 - PHARMAC is seeking feedback on a proposal to award Sole Supply Status in the community for leflunomide to ...
Posted by Michael Wonder on 08 Aug 2016
Decision relating to enoxaparin sodium and plerixafor
8 August 2016 - PHARMAC is pleased to announce the approval of an agreement with Sanofi-Aventis New Zealand Limited (Sanofi) for ...